Millions of individuals contract the virus known as dengue fever each year, which is mainly prevalent in tropical and subtropical regions. Dengvaxia, the first dengue vaccine, got regulatory approval in 2015. The development of a dengue vaccine has taken decades.
The live attenuated vaccine known as Dengvaxia offers some protection against all four dengue virus serotypes. It is administered in three doses over a six-month period and has been shown to reduce the incidence of severe dengue in persons who have had the immunisation. Dengvaxia's safety has still come under scrutiny, notably from people who have never been exposed to dengue.
One of the many dengue vaccine possibilities that are also in various stages of investigation is a recombinant vaccine called TAK-003, which has shown promise in clinical testing. TAK-003 uses a modified dengue virus to elicit an immune response without causing illness
Vaccination protection against dengue
Depending on the vaccine's kind and the recipient's age, the dengue vaccine's efficacy varies. According to studies, the CYD-TDV vaccine prevents dengue infection in adults over the age of nine with a 60% success rate. Nevertheless, the vaccine's efficacy is lower in younger children, with children between the ages of two and five only receiving 34% protection. In children between the ages of four and sixteen, the TV003/TAK-003 vaccination has demonstrated 80% efficiency against severe dengue and 97% effectiveness against dengue-related hospitalisation.
Read more:
.
Growth of the global dengue vaccine market is mainly driven by rising burden of dengue fever in tropical regions, large unmet medical need for managing dengue burden, promising end stage vaccine pipeline, development of live attenuated tetravalent dengue vaccine and expected local production of dengue vaccine in various countries are expected drive the market over forecasted period.Other prominent factors driving growth of the market are adoption/uptakeof dengue vaccine by various countries in dengue endemic regions of Latin America and Asia Pacific and increased governments interest to incorporate the vaccine in public immunization programmes in various countriesHowever, supply side infrastructure bottle necks such as surveillance system, standardized diagnostics practice, and cold chain systems for storage of vaccine in resource constrained countriesare the factors suggestive of barrier to growth of global Dengue Vaccinemarket.Players in thedengue vaccine development and in market are employing strategies to incorporate dengue vaccine in public immunization programs and vaccines in clinical stage development are being tested for safety and efficacy in all age groups and different transmission settings.
Request For Report Sample: https://www.researchreportinsights.com/report/sample/110114999/Dengue-Vaccine-Market Market SegmentationbyEnd UserBased on end user, the market has been segmented into hospitals, government institutes, and Non-Governmental Organizations (NGOs).
In terms of value, government institutesegment is estimated to account for more than 51.9% market share in global dengue vaccine market, by 2027 end.Key RegionsThe global Dengue Vaccinemarket has been segmented into four major regions:Latin America, Asia Pacific, Middle East & Africa (MEA), and Rest of the World (RoW).
In terms of value, the Asia Pacific markethas been estimated to dominate the global dengue vaccine market in 2017,and is expected to expand at a CAGR of 17.4% over the forecast period.
Latin America isexpected to be the fastest growing markets among regional markets.
Latin Americamarket is expected to witness highest CAGR of 18.0% over the forecast period.
UpMarketResearch offers a latest published report on “Global Dengue Vaccine Market Analysis and Forecast 2018-2025” delivering key insights and providing a competitive advantage to clients through a detailed report.
Get Free Exclusive PDF Sample Copy of This Report https://www.upmarketresearch.com/home/requested_sample/7489 Dengue Vaccine Industry research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.
Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
The numerical data is backed up by statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, PESTLE analysis and so on.
The statistics are represented in graphical format for a clear understanding on facts and figures.
The generated report is firmly based on primary research, interviews with top executives, news sources and information insiders.
It really is very important before you go travel you are familiar.
Dengue fever and yellow fever are.
Luckily, Alpha fever is vaccine preventable,Visit our website for fruitful information on: https://www.emailmeform.com/builder/emf/produkt/mosquito-block-reviews
Dengue Drugs Market OverviewDengue Drugs Market is expected to grow at a CAGR of 2.6% from 2019 to 2030Insightful data based on Dengue Drugs Market has been recently published by Absolute Markets Insights.
The report provides profound information on effective analysis of the businesses.
Moreover, the report uses an exploratory technique such as qualitative and quantitative analysis to discover the data of the market in question.
For instance, Indian Ministry of Science and Technology in partnership with Sun Pharmaceutical Industries Ltd. developed an herbal medicine for dengue in 2019.
Similarly, 60 Degrees Pharmaceuticals of Singapore was granted a patent for a novel dengue drug named Celgosivir in 2014.Access Full Report Details and Order this Premium Report @ https://www.absolutemarketsinsights.com/reports/Reusable-Shipping-Boxes-Market-2019-2030-617 Top Key Venders of Market:For instance, Indian Ministry of Science and Technology in partnership with Sun Pharmaceutical Industries Ltd. developed an herbal medicine for dengue in 2019.
These on-going developments of newer drugs are anticipated to drive the global dengue drugs market in forecast years.
